NAUT
Nautilus Biotechnology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.70
−14.17%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 424.0K | — | — | — | — |
| Cost of Revenue | 2.0M | 6.5M | 6.4M | 5.7M | — |
| Gross Profit | (1.5M) | (6.5M) | (6.4M) | (5.7M) | — |
| Operating Expenses | |||||
| R&D Expense | 40.1M | 41.1M | 50.5M | 47.3M | 37.7M |
| SG&A Expense | 25.4M | 25.7M | 31.0M | 28.9M | 25.9M |
| General & Admin Expense | 12.6M | 25.7M | 31.0M | 28.9M | 25.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (2.9M) | (6.5M) | (6.4M) | (5.7M) | — |
| Total Operating Expenses | 62.5M | 60.4M | 75.1M | 70.4M | 63.6M |
| Cost and Expenses | 64.5M | 66.8M | 81.5M | 76.2M | 63.6M |
| Operating Income (EBIT) | (64.0M) | (66.8M) | (81.5M) | (76.2M) | (63.6M) |
| Non-Operating | |||||
| Interest Income | 5.6M | 7.9M | 10.8M | 12.6M | 5.8M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 5.6M | 7.9M | 10.8M | 12.6M | 5.8M |
| Other Non-Op Income/Expense | 5.5M | 7.8M | 10.7M | 12.5M | 5.7M |
| Non-Operating Income (excl Interest) | (4.2M) | (7.8M) | (10.7M) | (12.5M) | (122.0K) |
| EBT (Pre-Tax Income) | (58.6M) | (59.0M) | (70.8M) | (63.7M) | (57.9M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (58.6M) | (59.0M) | (70.8M) | (63.7M) | (57.9M) |
| Earnings from Cont. Ops | (58.6M) | (59.0M) | (70.8M) | (63.7M) | (57.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (58.6M) | (59.0M) | (70.8M) | (63.7M) | (57.9M) |
| Per Share | |||||
| Basic EPS | ($0.46) | ($0.47) | ($0.56) | ($0.51) | ($0.46) |
| Diluted EPS | ($0.46) | ($0.47) | ($0.56) | ($0.51) | ($0.46) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 127.2M | 126.3M | 125.4M | 124.9M | 124.6M |
| Diluted Shares Outstanding | 127.2M | 126.3M | 125.4M | 124.9M | 124.6M |
| Profitability Metrics | |||||
| EBITDA | (54.2M) | (52.5M) | (64.4M) | (58.0M) | (60.1M) |
| D&A | 5.7M | 6.5M | 6.4M | 5.7M | 3.4M |
| EBIT | (59.9M) | (59.0M) | (70.8M) | (63.7M) | (63.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026